Y-mAbs Therapeutics, Inc. (YMAB)
After hours:
| Previous Close | 12.10 |
| Open | 12.12 |
| Bid | 12.04 x 100 |
| Ask | 12.12 x 100 |
| Day's Range | 12.01 - 12.96 |
| 52 Week Range | 4.60 - 20.90 |
| Volume | |
| Avg. Volume | 367,353 |
| Market Cap | 529.663M |
| Beta (5Y Monthly) | 0.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the publication of preclinical GD2-SADA data at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place May 31 through June 4, 2024, in Chicago, IL. T
- GlobeNewswire
Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting
NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced new interim data from the Phase 2 Trial 201 of naxitamab in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”) in patients with relapsed or refractory hi
- GlobeNewswire
Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments
Reported U.S. DANYELZA® net product revenues of $18.6 million for the first quarter of 2024, representing a YoY increase of 11% Reported Worldwide DANYELZA net product revenues of $19.4 million for the first quarter of 2024, representing a 4% YoY decrease due to international volumesCash and cash equivalents of $75.7 million as of March 31, 2024, and cash burn of only $2.9 million for the quarter ended March 31, 2024 Management reiterates full year 2024 financial guidance and anticipated cash ru
